Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?

NPM1 NPM1 CMML NPM1mut CMML AML CMML CMML treatment acute myeloid leukemia chronic myelomonocytic leukemia

Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
30 Sep 2024
Historique:
received: 09 12 2023
accepted: 20 04 2024
medline: 1 10 2024
pubmed: 1 10 2024
entrez: 30 9 2024
Statut: aheadofprint

Résumé

The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether CMML with NPM1 mutation (NPM1mut) should be diagnosed as AML. Nowadays, it is a subject of discussion because of its diagnostic and therapeutic implications. Therefore, we describe a case of a patient diagnosed with CMML NPM1mut and briefly review the literature to highlight the uncertainty about how to classify a CMML with NPM1 mutation. We emphasize the importance of a comprehensive molecular study, which is crucial to optimize the individualized treatment of patients, enabling them to access targeted therapies.

Identifiants

pubmed: 39349391
pii: 7797258
doi: 10.1093/oncolo/oyae246
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Instituto de Salud Carlos III (ISCIII)
ID : FIS PI19/01476
Organisme : Spanish Ministry of Education (VTM)

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press.

Auteurs

Sandra Castaño-Díez (S)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Universitat Barcelona, Barcelona, Spain.

José Ramón Álamo (JR)

Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Mònica López-Guerra (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Marta Gómez-Hernando (M)

Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Inés Zugasti (I)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Carlos Jiménez-Vicente (C)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Francesca Guijarro (F)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Universitat Barcelona, Barcelona, Spain.
Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Irene López-Oreja (I)

Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Daniel Esteban (D)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Paola Charry (P)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Víctor Torrecillas (V)

Universitat Barcelona, Barcelona, Spain.

Lucia Mont-de Torres (L)

Universitat Barcelona, Barcelona, Spain.

Albert Cortés-Bullich (A)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Álex Bataller (Á)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Universitat Barcelona, Barcelona, Spain.
Josep Carreras Leukemia Research Institute, Badalona, Spain.

Ares Guardia (A)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Daniel Munárriz (D)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Esther Carcelero (E)

Pharmacy Service, Hospital Clínic Barcelona, Barcelona, Spain.

Gisela Riu (G)

Pharmacy Service, Hospital Clínic Barcelona, Barcelona, Spain.

Ana Triguero (A)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Natalia Tovar (N)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Dolors Vela (D)

Hematology Department, Hospital General de Granollers, Granollers, Spain.

Silvia Beà (S)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Dolors Costa (D)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Dolors Colomer (D)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Maria Rozman (M)

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Hematopathology Section, Pathology Department, Hospital Clínic Barcelona, Barcelona, Spain.

Jordi Esteve (J)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Universitat Barcelona, Barcelona, Spain.
Josep Carreras Leukemia Research Institute, Badalona, Spain.

Marina Díaz-Beyá (M)

Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Josep Carreras Leukemia Research Institute, Badalona, Spain.

Classifications MeSH